

Clinical trials of colestipol-niacin

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
colestipol-niacin vs placebo			
CLAS , 1987 n=94/94 follow-up: 2 ans	Colestipol + Niacin 30 g / j 3-12 g / j (titr sur chaque patient sur la base de la baisse de cholestrol sanguin) versus placebo: methyl cellulose	Patients coronariens avec antcdent de revascularisation chirurgicale coronarienne.	Parallel groups Non dterminable
CLAS , 1987 n=NA follow-up: 65279;2 years	colestipol + niacin versus placebo	nonsmoking men aged 40 to 59 years with previous coronary bypass surgery	Parallel groups double blind

More details and results :

- cholesterol lowering intervention for cardiovascular prevention in patients with prior MI or with CHD at <http://www.trialresultscenter.org/go-Q12>
- cholesterol lowering intervention for cardiovascular prevention in all chronical situations at <http://www.trialresultscenter.org/go-Q154>
- niacin for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q326>

References

CLAS, 1987:

Blankenhorn DH, Brooks SH. Angiographic trials of lipid-lowering therapy. *Arteriosclerosis* 1981; 1: 242-249.

The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH *Control Clin Trials* 1987 Dec;8:356-87 [[3327654](#)]

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L *JAMA* 1987 Jun 19;257:3233-40 [[3295315](#)]

Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. Mack WJ, Selzer RH, Pogoda JM, Lee PL, Shircore AM, Azen SP, Blankenhorn DH *Arterioscler Thromb* 1992 Mar;12:348-56 [[1547194](#)]

CLAS, 1987:

Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. *Control Clin Trials* 1987;8:356-87 [3327654]

Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. *JAMA* 1990;264:3013-7 [2243429]

Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. *JAMA* 1987;257:3233-40 [3295315]

Blankenhorn DH, Azen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH, Shircore AM, Wickham EC Effects of colestipol-niacin therapy on human femoral atherosclerosis. *Circulation* 1991;83:438-47 [1991366]

2 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
colestipol-niacin vs placebo			
CLAS , 1987 n=94/94 follow-up: 2 ans	Colestipol + Niacin 30 g / j 3-12 g / j (titr sur chaque patient sur la base de la baisse de cholestrol sanguin) versus placebo: methyl cellulose	Patients coronariens avec antcdent de revascularisation chirurgicale coronarienne.	Parallel groups Non dterminable

More details and results :

- cholesterol lowering intervention for peripheral vascular diseases in all type of patients at <http://www.trialresultscenter.org/go-Q52>

References

CLAS, 1987:

Blankenhorn DH, Brooks SH. Angiographic trials of lipid-lowering therapy. *Arteriosclerosis* 1981; 1: 242-249.

The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH *Control Clin Trials* 1987 Dec;8:356-87 [3327654]

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L *JAMA* 1987 Jun 19;257:3233-40 [3295315]

Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. Mack WJ, Selzer RH, Pogoda JM, Lee PL, Shircore AM, Azen SP, Blankenhorn DH *Arterioscler Thromb* 1992 Mar;12:348-56 [1547194]

Entry terms: niacin, Niacin, Nicotinic Acid, 3-Pyridinecarboxylic Acid, 3 Pyridinecarboxylic Acid, Induracin, Niacin Ammonium Salt, Niacin Calcium Salt, Niacin Cobalt (2+) Salt, Niacin Lithium Salt, Niacin Magnesium Salt, Niacin Manganese (2+) Salt, Niacin Potassium Salt, Niacin Sodium Salt, Niacin Tartrate, Niacin Copper (2+) Salt, Niacin Hydrochloride, Niacin Iron (2+) Salt, Niacin Tosylate, Niacin

Zinc Salt, Nicamin, Nico-400, Nico 400, Nico400, Nicobid, Nicocap, Nicolar, Nicotinate, Wampocap, Enduracin, Lithium Nicotinate, Niacin Aluminum Salt,